пародонта." Журнал проблемы биологии и медицины 1 (107) (2019): 185
Исаходжаева, Хабиба, С. Маликов, and Д. Акрамова. "Изучение
гестационного возраста и массы тела новорожденного на сроки
прорезывание молочых зубов." in Library 22.1 (2022): 263
Даминова, Ш., Маткулиева, С., Назирова, С., & Абдиримова, Г. (2021).
Микробиологические и иммунологические показатели эффективности
лечении детей больных вирусным гепатитом «С». in Library, 21(2), 134–
извлечено от https://inlibrary.uz/index.php/archive/article/view/14500
Ризаев, Ж., and М. Юнусходжаева. "Биологические основы
остеорепарации и минерального обмена кости При лечении заболеваний
пародонта." Журнал проблемы биологии и медицины 1 (107) (2019): 185
микробиология, вирусология и иммунология." (2015).
EXPERIENCE WITH THE USE OF BACTERIAL LYSATES IN MODERN MEDICINE
Bukhara state medical institute
Among drugs that stimulate immune processes and specifically activate
immunocompetent cells (T- and B-lymphocytes) and additional immunity factors
(macrophages, secretory immunoglobulins, etc.). There are immunomodulators
of microbial origin containing lipopolysaccharide complexes (prodigiosan,
pyrogenal), bacterial ribosomes in combination with membrane proteoglycans
(ribomunal). Among immunocorrective drugs, immunomodulators of microbial
origin are of interest, which are divided into three main groups - purified bacterial
lysates, immunostimulating membrane fractions and bacterial ribosomes in
combination with membrane fractions.
Specially created for dental practice, Imudon (manufactured by the
international pharmaceutical company Solvay Pharma) belongs to the group of
purified bacterial lysates. The drug is made from a mixture of lysates of strains of
the most common bacterial and fungal pathogens of pathological processes in the
oral cavity. Among them are Lactobacillus acidophicus, Str. aureus,
Kl.pheumoniae, Corinobacterium, Pseudodiphtericum, Candida albicans and
others. The drug is a polyvalent complex of antigens that can cause the formation
of antibodies. Imudon increases FAN, increases the content of lysozyme in saliva,
stimulates the formation of immunocompetent cells and the amount of slgA.
Grigoryants L.I. and Badalyan V.A. (2000) recommend taking up to 10 tablets per
day for an acute process in the oral cavity with an average duration of up to 10
days. In chronic diseases - up to 6 tablets per day for 10-20 days, for the
prevention and treatment of postoperative complications
The introduction of IRS-19 through the mucous membranes of the
upper respiratory tract is justified by the anatomical, physiological and
immunological conditions in the nasopharynx. Due to these anatomical and
physiological conditions, IRS-19 can penetrate extremely quickly and intensively
through the mucosa into the div, thereby causing an immediate mobilization of
defense mechanisms in the mucosa and triggering the effective production of
The local immune system responsible for protection against infection on the
surface of the mucous membranes can also be subject to a wide variety of
disorders. These dis orders can bee ither primary or secondary. Along with
primary disorders of the immune system, secondary disorders are the most
common cause of chronic recurrent respiratory tract infections in children. The
risk of infection is particularly increased due to the fact that the factors
responsible for impaired mucociliary defenses also impair the immune system.
This applies to both external factors and infectious pathogenic microorganisms,
which include bacteria and viruses.
When immunity is deregulated under the action of a bacterium, suppression
of the immune system can occur, due to both secretion products and endotoxins
released during bacteriolysis. As a result of the use of IRS-19 in patients with
diseases of the upper respiratory tract and certain dental diseases, a number of
authors have achieved a high therapeutic effect and reduced the development of
disease relapses. Since the drug IRS-19 has a good therapeutic effect in diseases
of the upper respiratory tract and ENT organs, it would be advisable to investigate
the effect of this drug in diseases of the oral cavity, in particular, odontogenic
periostitis of the jaws in children, because diseases of the oral cavity are caused
by the same microorganisms that occur and for the diseases mentioned above. In
addition, children after surgery in the oral cavity refuse to suck imudon. In the
available literature, we did not find information on the study of the effectiveness
of the IRS-19 drug in the treatment of odontogenic periostitis of the jaws. In this
regard, the study of the effectiveness of the drug IRS-19 in children with
odontogenic periostitis of the jaws was of particular interest to us.
Conclusion: Being very active physiologically, it forms the entrance gate for
most infectious agents and serves as a kind of collection point for them in case of
congenital or acquired immune deficiency. Due to the indicated anatomical and
physiological conditions, IRS-19 can penetrate the mucous membrane extremely
quickly and intensively, thereby causing an immediate mobilization of the
protective mechanisms in it, triggering the effective production of antibodies.
Only with the help of surgical intervention can the damaging factor itself be
eliminated and, thus, the div's defenses be given the opportunity to recover.
Даминова, Ш., & Маткулиева, С. (2020). Изучение чувствительности
микробов к некторым лекарственным препаратам в условиях
in vitro!. in
CHILDRENКОРОНАВИРУСНАЯ Turaeva F.A.
. "Современный взгляд на этиопатогенез
аномалий прорезывания зубов." Медицина и инновации 1.2 (2
Даминова, Ш., С. Маткулиева, С. Назирова, и Н. Раззакова.
«Нарушения биологии полости рта у детей с гепатитом С».
, т. 21,
М. Юнусходжаева. "ОСОБЕННОСТИ ТЕЧЕНИЯ
АГРЕССИВНЫХ ФОРМ ПАРОДОНТИТОВ."
Stomatologiya 1.2 (75) (2019): 24-26
. "ВЛИЯНИЕ ГЕСТАЦИОННОГО ВОЗРАСТА И
Stomatologiya 1.1 (82) (2021): 40-42.
THE ORAL MUCOSA CORONAVIRUS PATHOLOGIES IN CHILDREN
Bukhara State Medical Institute
Annotation. The persistence and recurrent nature of such inflammatory
lesions requires not only the usual hygienic measures for the care of the oral
cavity and teeth, but also appropriate justified therapy aimed at stimulating the
protective forces of the oral mucosa.
Relevance of the topic.Macrophages, through the release of cytokines, play
a major role in the protective mechanism, causing an increase in the level of T
lymphocytes. The occurrence of non
specific infectious and inflammatory
diseases of the pharynx and upper respiratory tract occurs due to an imbalance
of local and systemic immunity. The leading role in local immunity is played by
cytokines acting on biochemical messengers that regulate the stimulation and
inhibition of inflammatory reactions that initiate an immune response. Cytokines
are produced by lymphocytes and macrophages embedded in the epithelium of
the mucous membrane, the source of cytokines in saliva is serum transudate and
salivary glands. Cytokines are also produced by the epithelial cells of the mucous
membrane themselves when they come into contact with a microbe. It is
important to note that the content of cytokines in saliva does not correlate with
their level in the blood, which indicates the autonomy of local immunity. Viral
infection can serve as an initiating factor for the attachment of a bacterial